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Dear Editor, 
 
Symptomatic aortic valvular stenosis (AS) leads to significant morbidity or mortality [1] unless treated with surgical aortic valve 
replacement (sAVR) or, for high-risk/inoperable sAVR patients, transcatheter aortic valve implantation (TAVI). Whilst mortality 
rates and hospital length of stay (LOS) appear similar with both procedures, reduced intensive care LOS in TAVI patients might 
suggest different patterns of morbidity [1].  
 
Comparing morbidity after sAVR and TAVI has been hampered by heterogeneous morbidity definitions and lack of validated 
assessment tools [2]. We thus used the first validated post-operative morbidity assessment tool  (the Cardiac Post-operative 
Morbidity Score, C-POMS) [3] - to describe and quantify postoperative morbidity in consecutive single-centre patients undergoing 
sAVR and TAVI between January 2012 and January 2013. C-POMS represents total morbidity as a summary score (0-13), derived 
by prospectively noting the presence or absence of 13 morbidity domains (Table 1) on days 3 (D3), 5 (D5), 8 (D8) and 15 (D15). 
Prior to formal data collection, two-person inter-rater reliability was excellent (Kappa agreement >0.7 (defined a priori) across all 
domains. All statistical tests were two-tailed.  Statistical significance was taken at the p<0.05 level. 
 
In total, 136 patients underwent sAVR, and 53 patients TAVI. Five TAVI patients discharged before D3 were excluded from the 
analysis as C-POMS is an in-hospital morbidity assessment tool and therefore no morbidity data was available. All patients 
underwent TAVI under general anaesthesia. Compared to sAVR patients, TAVI patients were older (mean age 81±7.3 years vs. 
67±13.2 years, p=0.000), more likely to have preceding neurological disease (26.4 vs. 7.5%, p=0.001) and a higher EuroSCORE I 
(9.6±2.5 vs. 5.9±2.7, p=0.000), and less likely to be in sinus rhythm (57.7% vs. 87.5%, p=0.000).   
 
Median (IQR) LOS was 8 (6) days in the sAVR group and 4 (6) days in the TAVI group (p=0.32). Table 1 shows the proportion of 
patients with each C-POMS criterion.  Mean C-POMS scores were higher in the sAVR group on D3 (4.9±1.9 vs. 3.16±2.4, 
p=0.001) but higher in the TAVI group on D15 (5.86±1.9 vs. 3.76±2.3, p=0.042). There were 5 deaths in the TAVI group – 1 on 
D5, 1 on D9 and 3 after D15, and none in the sAVR group. Significantly more sAVR patients (n (%)) required pacing (either 
pacing wires/PPM) on D5 (56 (42.7%) vs. 3 (12.5%), p=0.005) and there was an increasing trend in the sAVR group on other days 
(D8: 23 (29.1%) vs. 2 (11.8%), p=0.223), D15: 4 (16%) vs. 1 (14.3%), p=1.000). Pulmonary and ambulation morbidity was 
prevalent in both groups at all time points suggestive of an association, and infectious morbidity peaked in both groups on D8.  
 
Our pilot study suggests that although TAVI patients had a greater surgical risk than sAVR patients, hospital LOS was similar in 
both groups. The use of C-POMS has shown that different post-operative morbidity patterns exist between the two groups. Our 
results support performing a larger study to better characterise these patterns. Such data might help in risk assessment, resource 
management, and in identification of prophylactic or therapeutic targets to reduce morbidity.  
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Table 1. Proportion of patients with each C-POMS criteria. Values are n(%). Criteria defining the morbidity types are not 
mutually exclusive. Figures in bold are statistically significant (p<0.05) 
 D3 D5 D8 D15 
Morbidity type AVR 
(n=136) 
TAVI 
(n=49) 
AVR 
(n=131) 
TAVI 
(n=24) 
AVR 
(n=79) 
TAVI 
(n=17) 
AVR 
(n=25) 
TAVI 
(n=7) 
Pulmonary  126 (92.6) 24 (49.0) 83 (63.4) 12 (50.0) 45 (57.0) 10 (58.8) 12 (48.0) 6 (85.7) 
Infectious 46 (33.8) 9 (18.4) 51 (38.9) 6 (25.0) 38 (48.1) 8 (47.1) 9 (36.0) 4 (57.1) 
Renal 117 (80.0) 26 (53.1) 65 (49.6) 14 (58.3) 24 (30.4) 10 (58.8) 13 (52.0) 6 (85.7) 
Gastrointestinal 15 (11.0) 7 (14.3) 15 (11.5) 7 (29.2) 11 (13.9) 7 (41.2) 8 (32.0) 5 (71.4) 
Cardiovascular 63 (46.3) 18 (36.7) 76 (58.0) 7 (29.2) 42 (53.2) 5 (29.4) 12 (48.0) 4 (57.1) 
Neurological 15 (11.0) 8 (16.3) 13 (9.9) 5 (20.8) 7 (8.9) 5 (29.4) 3 (12.0) 4 (57.1) 
Haematological 61 (44.9) 15 (30.6) 53 (40.5) 4 (16.7) 28 (35.4) 2 (11.8) 6 (24.0) 0 (0.0) 
Wound 39 (28.7) 1 (2.0) 15 (11.5) 0 (0.0) 8 (10.1) 2 (11.8) 3 (12.0) 1 (14.3) 
Pain 46 (33.8) 9 (18.4) 27 (20.6) 3 (12.5) 17 (21.5) 1 (5.9) 3 (12.0) 1 (14.3) 
Endocrine 17 (12.5) 4 (8.2) 15 (11.5) 4 (16.7) 12 (15.2) 4 (23.5) 0 (0.0) 2 (28.6) 
Electrolyte 41 (30.1) 6 (12.2) 30 (22.9) 4 (16.7) 7 (8.9) 2 (11.8) 5 (20.0) 1 (14.3) 
Review 20 (14.7) 8 (16.3) 26 (19.8) 4 (16.7) 15 (19.0) 5 (29.4) 9 (36.0) 3 (42.9) 
Ambulation 59 (43.4) 20 (40.8) 40 (30.5) 10 (41.7) 25 (31.6) 8 (47.1) 10 (40.0) 4 (57.1) 
C-POMS 
summary score 
Mean 
Min 
Max 
SD 
 
 
4.90 
0 
10 
1.929 
 
 
3.16 
0 
8 
2.418 
 
 
3.88 
0 
10 
2.229 
 
 
3.33 
0 
10 
2.729 
 
 
3.53 
0 
10 
2.347 
 
 
4.06 
0 
10 
2.794 
 
 
3.76 
0 
9 
2.385 
 
 
5.86 
3 
8 
1.952 
 
 
 
